In This Issue
Marketing Ahead of Science: IORT for Early-Stage Breast Cancer
New SAVI Data at 2014 ABS
2014 ASBrS Preview
BrachyBytes Editorial Advisory Board

Robert Kuske, M.D.

Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
Catheryn Yashar, M.D.
Vic Zannis, M.D.
Upcoming Events

American Society of Breast Surgeons

April 30-May 4, 2014
Las Vegas, NV
Website
Booth #208

Become a Center of Excellence in APBI

Learn about becoming a Center of Excellence and find ways to grow your APBI program by reaching out to referring physicians and women in the community.

Contact info@ciannamedical.com for more information.  
Follow-up Links

Past Issues
Cianna Medical

BEST Forum
SAVI Sisters

The Cancer Institute of New Jersey

US San Diego Moores Cancer Center
Texas Oncology

April 2014  

Marketing Ahead of Science:
IORT for Early-Stage Breast Cancer 
Atif Khan, MD   

Intraoperative radiation therapy (IORT) is a method of accelerated partial breast irradiation (APBI) that allows for treatment at the time of lumpectomy. Last fall, updated results from two Phase III studies – the TARGIT-A trial and the ELIOT trial – were published in The Lancet and The Lancet Oncology. Both trials, which compare IORT to standard whole breast irradiation, reported significantly higher recurrence rates in the IORT arms.

In addition to inferior local control, physicians often cite other limitations of IORT, including treating without complete pathologic information, unproven radiobiology, and a lack of image guided treatment planning.

Radiation oncologist Atif Khan, MD, of The Cancer Institute of New Jersey, New Brunswick, NJ, shares his views on IORT, the reasons behind its rapid adoption, and how the recently published data do not support a role for IORT in the management of early-stage breast cancer. Read more

New SAVI Data at 2014 ABS

At the 2014 meeting of the American Brachytherapy Society, researchers from the SAVI Collaborative Research Group presented the results of a retrospective study of patients with ductal carcioma in situ (DCIS) treated with strut-based brachytherapy. They reported excellent local control, with recurrence rates that appear to be equivalent to those expected for whole breast irradiation with similar follow-up.

“This study adds to the growing body of research showing that brachytherapy-based APBI is a safe and effective treatment for DCIS patients,” said lead author John Einck, MD, a radiation oncologist at the UC San Diego Moores Cancer Center, La Jolla, Calif. Read more

In addition, researchers from Texas Oncology presented a five-year retrospective review of their clinical experience with the SAVI 6-1Mini applicator. They concluded the miniature strut-based device proves to be a “versatile APBI solution” for complex breast cancer cases, including patients with small breasts and/or lumpectomy cavities, as well as skin and/or rib bridges. View poster

2014 ASBrS Preview

Heading to Las Vegas for the 15th annual meeting of the American Society of Breast Surgeons? If so, don’t miss the latest data on strut-based brachytherapy from the SAVI Collaborative Research Group:

Strut-based Brachytherapy in 113 Patients (114 Breasts) with 5mm or Less Skin Bridge Thickness and Median Follow Up of 33 Months
Jon Strasser, MD & Emily Penman, MD

Christiana Care Health System, Newark, DE

Poster Session & Reception
Friday, May 2, 2014
6:00-7:30 pm
Grand Ballroom

And don’t forget to visit Cianna Medical at Booth #208 – see you there!